Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

1. In COPD puffers, does three-of-kind beat a pair?

In COPD puffers, does three-of-kind beat a pair? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 3500 family physicians, family medicine residents and medical students in Alberta. Established over fifty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca June 24, 2019 In COPD (...) puffers, does three-of-kind beat a pair? Clinical Question: In Chronic Obstructive Pulmonary Disease (COPD) patients on Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting Beta-Agonist (LABA) dual therapy, does adding inhaled corticosteroids (ICS) improve outcomes? Bottom Line: In COPD patients with =1 exacerbation per year, triple therapy reduces the risk of future exacerbations compared to LAMA/LABA dual therapy (one less in 36 patients/year) but increases the risk of pneumonia (one more in 34

2019 Tools for Practice

2. Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality. (PubMed)

Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality. According to numerous current guidelines, the diagnosis of chronic obstructive pulmonary disease (COPD) requires a ratio of the forced expiratory volume in the first second to the forced vital capacity (FEV1:FVC) of less than 0.70, yet this fixed threshold is based on expert opinion and remains controversial.To determine the discriminative accuracy of various FEV1:FVC fixed thresholds for predicting (...) COPD-related hospitalization and mortality.The National Heart, Lung, and Blood Institute (NHLBI) Pooled Cohorts Study harmonized and pooled data from 4 US general population-based cohorts (Atherosclerosis Risk in Communities Study; Cardiovascular Health Study; Health, Aging, and Body Composition Study; and Multi-Ethnic Study of Atherosclerosis). Participants aged 45 to 102 years were enrolled from 1987 to 2000 and received follow-up longitudinally through 2016.Presence of airflow obstruction, which

2019 JAMA

3. Benralizumab for the Prevention of COPD Exacerbations. (PubMed)

Benralizumab for the Prevention of COPD Exacerbations. The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a ratio of approximately 2:1 on the basis of eosinophil count [≥220 per cubic millimeter vs. <220 per cubic millimeter (...) ]) who had frequent exacerbations despite receiving guideline-based inhaled treatment. Patients were randomly assigned to receive benralizumab (30 or 100 mg in GALATHEA; 10, 30, or 100 mg in TERRANOVA) every 8 weeks (every 4 weeks for the first three doses) or placebo. The primary end point was the treatment effect of benralizumab, measured as the annualized COPD exacerbation rate ratio (benralizumab vs. placebo) at week 56 in patients with baseline blood eosinophil counts of 220 per cubic millimeter

2019 NEJM

4. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. (PubMed)

Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. There is concern that long-acting muscarinic antagonists increase cardiovascular morbidity or mortality in patients with chronic obstructive pulmonary disease (COPD).To determine the cardiovascular safety (noninferiority) and efficacy (superiority) of aclidinium bromide, 400 μg twice daily, in patients (...) with COPD and cardiovascular disease or risk factors.Multicenter, randomized, placebo-controlled, double-blind, parallel-design study conducted at 522 sites in North America. A total of 3630 patients with moderate to very severe COPD and either a history of cardiovascular disease or at least 2 atherothrombotic risk factors were randomized; follow-up occurred for up to 3 years until at least 122 major adverse cardiovascular events (MACE) occurred. The first patient was enrolled on October 16, 2013

2019 JAMA

5. Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD

Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination is commonly prescribed to treat COPD; therefore, we performed a meta-analysis on the effect of adding a long-acting muscarinic receptor antagonist (LAMA) to ICS/LABA combination in COPD.Studies were identified by searching in different databases the randomized controlled trials that investigated the effect of ICS/LABA/LAMA combination (...) in COPD. The primary end points were the effect of triple therapy on trough FEV1, risk of acute exacerbation of COPD (AECOPD), and risk of cardiovascular serious adverse events (SAEs), compared with ICS/LABA combination. The Grading of Recommendations Assessment, Development, and Evaluation system was used to assess the quality of evidence.Thirteen randomized controlled trials including 15,519 patients with COPD (ICS/LABA/LAMA combination, 53.1%; ICS/LABA combination, 46.9%) were meta-analyzed. ICS

2019 EvidenceUpdates

6. Glycopyrronium / formoterol fumarate dihydrate (Bevespi Aerosphere) - chronic obstructive pulmonary disease (COPD)

Glycopyrronium / formoterol fumarate dihydrate (Bevespi Aerosphere) - chronic obstructive pulmonary disease (COPD) EMA/752588/2018 EMEA/H/C/004245 Bevespi Aerosphere (glycopyrronium bromide / formoterol) An overview of Bevespi Aerosphere and why it is authorised in the EU What is Bevespi Aerosphere and what is it used for? Bevespi Aerosphere is a medicine used in adults to relieve the symptoms of chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways (...) only be obtained with a prescription. For more information about using Bevespi Aerosphere, see the package leaflet or contact your doctor or pharmacist. How does Bevespi Aerosphere work? The two active substances in Bevespi Aerosphere work in different ways to widen the airways and improve breathing in COPD. Glycopyrronium bromide is a muscarinic receptor antagonist. This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs. Because these receptors help control

2019 European Medicines Agency - EPARs

7. Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials

Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials Randomised controlled trials (RCTs) of vitamin D to prevent COPD exacerbations have yielded conflicting results.Individual participant data meta-analysis could identify factors that explain this variation.PubMed, Embase, the Cochrane Central Register of Controlled Trials and Web of Science were searched from inception up to and including 5 October 2017 (...) to identify RCTs of vitamin D supplementation in patients with COPD that reported incidence of acute exacerbations. Individual participant data meta-analysis was performed using fixed effects models adjusting for age, sex, Global Initiative for Chronic Obstructive Lung Disease spirometric grade and trial.Four eligible RCTs (total 560 participants) were identified; individual participant data were obtained for 469/472 (99.4%) participants in three RCTs. Supplementation did not influence overall rate

2019 EvidenceUpdates

8. Cluster-randomised trial of a nurse-led advance care planning session in patients with COPD and their loved ones

Cluster-randomised trial of a nurse-led advance care planning session in patients with COPD and their loved ones Advance care planning (ACP) is uncommon in patients with chronic obstructive pulmonary disease (COPD).To assess whether a nurse-led ACP-intervention can improve quality of patient-physician end-of-life care communication in patients with COPD. Furthermore, the influence of an ACP-intervention on symptoms of anxiety and depression in patients and loved ones was studied. Finally (...) , quality of death and dying was assessed in patients who died during 2-year follow-up.A multicentre cluster randomised-controlled trial in patients with advanced COPD was performed. The intervention group received an 1.5 hours structured nurse-led ACP-session. Outcomes were: quality of patient-physician end-of-life care communication, prevalence of ACP-discussions 6 months after baseline, symptoms of anxiety and depression in patients and loved ones and quality of death and dying.165 patients were

2019 EvidenceUpdates

9. Adding low dose theophylline to inhaled corticosteroids does not reduce COPD exacerbations

Adding low dose theophylline to inhaled corticosteroids does not reduce COPD exacerbations Adding low dose theophylline to inhaled corticosteroids does not reduce COPD exacerbations Discover Portal Discover Portal Adding low dose theophylline to inhaled corticosteroids does not reduce COPD exacerbations Published on 15 January 2019 doi: Taking low-dose theophylline tablets in addition to inhaled corticosteroids did not significantly reduce chronic obstructive pulmonary disease flare-ups (...) -inflammatory effects of inhaled steroids and therefore could be useful for those who continue to suffer exacerbations and hospital admissions. However, the results of this study confirm guideline recommendations that, for the majority of people, the combination of oral theophylline plus inhaled steroid is not useful. Share your views on the research. Why was this study needed? Chronic obstructive pulmonary disease (COPD) is a progressive lung disease costing the NHS approximately £1 billion annually

2019 NIHR Dissemination Centre

10. One week of steroids may be as effective as two weeks in managing severe COPD

One week of steroids may be as effective as two weeks in managing severe COPD One week of steroids may be as effective as two weeks in managing severe COPD Discover Portal Discover Portal One week of steroids may be as effective as two weeks in managing severe COPD Published on 10 July 2018 doi: A shorter course of steroids lasting 3 to 7 days appears as effective as the recommended 7 to 14-day standard treatment for managing a flare-up of severe chronic obstructive pulmonary disease (...) study sizes and including only 582 people in total. Further research is needed to determine the optimum duration of steroid treatment in flare-ups of mild or moderate chronic obstructive pulmonary disease. Share your views on the research. Why was this study needed? Chronic obstructive pulmonary disease (COPD) is a group of lung diseases commonly associated with smoking that cause breathing difficulty. The World Health Organization estimates that 64 million people have COPD and that it will become

2019 NIHR Dissemination Centre

11. Use of a facemask ventilator can reduce deaths in severe flare-ups of COPD

Use of a facemask ventilator can reduce deaths in severe flare-ups of COPD Use of a facemask ventilator can reduce deaths in severe flare-ups of COPD Discover Portal Discover Portal Use of a facemask ventilator can reduce deaths in severe flare-ups of COPD Published on 19 September 2017 doi: People admitted to hospital with a severe exacerbation of chronic obstructive pulmonary disease (COPD) were 46% less likely to die if they received non-invasive ventilation. Only 12% of those receiving non (...) -invasive ventilation needed subsequent invasive ventilation via a tube, compared to 34% of those who had usual care. This review identified 17 trials of adults with a severe acute exacerbation of COPD with high carbon dioxide levels. Trials compared usual care, including steroids and antibiotics with usual care plus non-invasive ventilation, which delivers air at high pressure via a mask. Airways are forced open and respiratory muscles can rest. This updated review shows benefits of immediate treatment

2019 NIHR Dissemination Centre

12. Pneumococcal vaccines for people with COPD reduce their chance of catching pneumonia

Pneumococcal vaccines for people with COPD reduce their chance of catching pneumonia Pneumococcal vaccines for people with COPD reduce their chance of catching pneumonia Discover Portal Discover Portal Pneumococcal vaccines for people with COPD reduce their chance of catching pneumonia Published on 30 May 2017 doi: Pneumococcal vaccines reduce the risk of community-acquired pneumonia in people with moderate to severe chronic obstructive pulmonary disease (COPD). Pneumococcal vaccination (...) is currently recommended for people with COPD and other respiratory diseases. However, until now there has been a lack of data whether it actually improves outcomes in these groups. This updated Cochrane review identified 12 trials including 2171 adults with COPD, comparing those who did and did not receive pneumococcal vaccination. One episode of community-acquired pneumonia was prevented for every 21 people vaccinated. There was also evidence that vaccination reduced the risk of exacerbations of COPD

2019 NIHR Dissemination Centre

13. Potential alternative to painful blood tests in people with flare-ups of COPD

Potential alternative to painful blood tests in people with flare-ups of COPD Potential alternative to painful blood tests in people with flare-ups of COPD Discover Portal Discover Portal Potential alternative to painful blood tests in people with flare-ups of COPD Published on 27 September 2016 doi: It may be possible to use venous blood and pulse oximeters to initially assess the severity of a flare up of chronic obstructive pulmonary disease (COPD). Blood gas levels were similar in people (...) when testing blood from either arteries (the recommended test) or veins. Oxygen saturation using pulse oximeters – which attach to the end of the finger – were also reasonably accurate compared to testing arterial blood. Flare-ups of COPD – where the person’s condition suddenly deteriorates – are the second most common cause of emergency hospital admissions in the UK. It is important to assess how serious a flare-up is by testing blood for gases such as carbon dioxide and oxygen. Taking an arterial

2019 NIHR Dissemination Centre

14. Reviewing inhaler technique for older people with COPD can improve disease control

Reviewing inhaler technique for older people with COPD can improve disease control Reviewing inhaler technique for older people with COPD can improve disease control Discover Portal Discover Portal Reviewing inhaler technique for older people with COPD can improve disease control Published on 22 January 2019 doi: Educating older adults with chronic obstructive pulmonary disease or asthma about the correct way to use their inhalers, as part of disease management, can reduce their risk (...) , regularly ensuring good technique should prevent unnecessary increases in inhaler doses or additional treatments and is considered good practice. It may also be cost effective if it reduces exacerbations requiring hospital admission. Share your views on the research. Why was this study needed? Approximately 1.2 million people have been diagnosed with chronic obstructive pulmonary disease (COPD) in the UK while eight million have asthma. Inhaled short and long-acting bronchodilators and corticosteroids

2019 NIHR Dissemination Centre

15. People with COPD exacerbations prefer early discharge then treatment at home

People with COPD exacerbations prefer early discharge then treatment at home Hospital at home treatment for COPD flare-ups Discover Portal Discover Portal People with COPD exacerbations prefer early discharge then treatment at home Published on 11 December 2018 doi: People with flare-ups of COPD (chronic obstructive pulmonary disease) prefer to be managed at home rather than in hospital. Hospital stay was on average four days shorter when people were discharged early to the hospital at home (...) in hospital which should probably give cost savings, although the hoped for benefit of a reduction in readmissions was not realised. Share your views on the research. Why was this study needed? Chronic obstructive pulmonary disease (COPD) is the name of a group of lung disorders that cause increasing difficulty in breathing over time. Almost 2% of people in England have COPD, mostly middle aged or older long term smokers. COPD usually progresses slowly, but people can have sudden worsening known

2019 NIHR Dissemination Centre

16. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis

Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis We performed a meta-analysis to compare the impact of triple combination therapy with inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic receptor antagonists (LAMAs) versus LABA/LAMA combination therapy or single long-acting bronchodilator therapy in chronic obstructive pulmonary disease. The ICS/LABA/LAMA combination reduced the risk

2019 EvidenceUpdates

17. COPD exacerbation: no systematic use of antibiotics

COPD exacerbation: no systematic use of antibiotics Prescrire IN ENGLISH - Spotlight ''COPD exacerbation: no systematic use of antibiotics'', 1 January 2019 {1} {1} {1} | | > > > COPD exacerbation: no systematic use of antibiotics Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight COPD exacerbation: no systematic use of antibiotics For episodes (...) of moderate aggravation in patients with chronic obstructive pulmonary disease (COPD), it is preferable to prescribe antibiotics as a first-line treatment only when the suspicion of bacterial infection is reinforced by an increase in sputum purulence. Patients with chronic obstructive pulmonary disease (COPD) are subject to exacerbations of their disease, i.e. episodes of prolonged aggravation. The known causes are mainly viral and bacterial infections. Some exacerbations justify hospitalisation: severe

2019 Prescrire

18. Revefenacin (Yupelri) - To treat patients with chronic obstructive pulmonary disease (COPD)

Revefenacin (Yupelri) - To treat patients with chronic obstructive pulmonary disease (COPD) Drug Approval Package: Yupelri (revefenacin) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Yupelri (revefenacin) Company: Theravance Biopharma Ireland Limited Application Number: 210598 Approval Date: 11/09/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling

2019 FDA - Drug Approval Package

19. Blended interventions to reduce the disease burden of COPD and asthma patients: a systematic review

Blended interventions to reduce the disease burden of COPD and asthma patients: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

20. The efficacy and safety of Traditional Chinese Medicine (TCM) therapy for anxiety or depression in patients with stable COPD-a systematic review and meta-analysis of randomised controlled trials

The efficacy and safety of Traditional Chinese Medicine (TCM) therapy for anxiety or depression in patients with stable COPD-a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO